Antengene

Developer of small molecule drugs for the treatment of cancer and autoimmune diseases

placeShanghai, Shanghai, China calendar_todayFounded 2015 groups359 employees language antengene.com

Social engagement

Social engagement: 6.2K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

13 investors on record; lead investors include FountainVest Partners, Boyu Capital, Qiming Venture Partners, Fidelity Investments.

Investor typeCountShare
Venture capital323%
Private equity538%
Other / undisclosed538%

Recent activity

16 Jun 2026
Event
J.P. Morgan's European Healthcare Symposium 2026
11 Jun 2026
Event
2026 BIO International Convention
20 May 2026
Leadership hire
Chief Scientific Officer
Coming soon